How CPMA works and how it differs from pre-existing treatment options
Sponsored by Elanco Animal Health
Adam Christman, DVM, MBA
You've heard a lot about monoclonal antibodies out there, it's been in the literature, we've had some comfort using it. But specifically, what is the target of CPMA?
Michael Lappin, DVM, PhD, DACVIM
Yeah, so basically, it's antibodies against Parvo. And it's just like if your body had had time to make antibodies from the vaccination, or you still had maternal antibodies at a level enough to help neutralize virus, that'd be great. That way, you know, didn't make natural antibodies yet from the vaccine, my mom's antibodies have waned, I now have Parvo replicating in my blood. This is a viremia treatment, as we've already mentioned, it's going to neutralize to lessen the next set of cells becoming infected. So it's truly just serum neutralization, with a standardized production process, giving you that nice consistent, every batch is the same, we know exactly how many antibody molecules are in a vial. And so that standardization is why this is probably going to be more successful than the previous publications, trying to use hyperimmune serum. Because there would be variation from dose to those weren't giving a nice consistent, and then the targets that they chose, were also brilliant, because doing the pathway that they've done to make their mind, body should also make sure to cover different strain variations. People are always asking me about C2B versus 2C. And so this particular scientific process that they've used looks like cross protection, or cross neutralization, excuse me, would likely to continue far into the future.CP, many injections. But 1 intravenous injection compared to current treatment modalities that are out there. Well, it will be an additive for us. We're still going to offer fluid therapy for the dehydrated animal for the bacteremic animal, antibiotics, glucose for the hypoglycemic. And obviously, we also have to repeat them with potassium because they lose so much in their GI tract. And so this would then be added to those things, to lessen the virus damage, more damage, basically, and continuing the symptoms.
Erik Zager, DVM, DACVECC
I think one of the good things from the team's perspective is this is not a very labor intensive treatment, which is really important. You know, they're they're frozen, you thaw them, you draw them up, inject them into the patient, you're done. It's a one time injection. And so, it takes 10 times as long to do subcutaneous fluids as I used to do this injection. And so, when first we got these things, and our staff was worried, like, alright, what new hoops am I going to have to jump through to try to do this because we're already so taxed by treating these Parvo patients? It's like, well, now you just give it injection. It's faster than you would give IV antibiotics even. So, that is definitely a very helpful factor in this treatment.
Adam Christman, DVM, MBA
And from a shelter perspective, too, it's got to be much more easier to knowing that just a one time injection. So what does that look like from a shelter perspective?
Yeah, it really didn't, you know, extend the treatment at all like, like he said, It's very quick. It's very efficient. And that being a high volume, we have to be super efficient, and really minimize treatment times to under 15 minutes for each pet. And so when my team was able to do it, they were like, wow, this is really easy. Like yeah, it doesn't, you know, really change anything but the potential for it is incredible.